---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-046728"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:15:53.791660+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics reports Q3 net loss of $11.2M; NAVIGATE trial top-line results expected Dec 2024

## Summary
- Net loss $11.2M ($0.18/share) vs $14.0M ($0.24) in Q3 2023; R&D expense $7.6M, G&A $1.5M.
- Cash $27.1M at Sept 30, 2024; $6M credit line from chairman; runway through May 2025.
- NAVIGATE trial of belapectin in MASH cirrhosis top-line efficacy/safety results expected December 2024.
- Three belapectin abstracts accepted for poster presentation at AASLD 2024 annual meeting.
- Annual stockholder meeting set for January 23, 2025 due to NAVIGATE trial timing.

## SEC filing metadata
- accession: 0001140361-24-046728
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/0001140361-24-046728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/ef20038321_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-046728
- JSON: https://secwatch.observer/filing/0001140361-24-046728.json
- Plain text: https://secwatch.observer/filing/0001140361-24-046728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.